Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

The company plans to file an investigational new drug application with the FDA later this year to advance an internally developed dual amylin and ... reduced plasma levels of very long-chain ...

The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor ... while driving significant reductions in plasma levels of very long-chain fatty ...

Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient. Secures Dedicated Fill/Finish Capacity for 100 Million Annua ...

The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor ... while driving significant reductions in plasma levels of very long-chain fatty ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

A powerful new plasma engine has just been unveiled by Chinese engineers – and it is expected to propel China ahead of the United States in the race to develop plasma technology for Mars and ...

The candidate is a long-acting amylin analog for the treatment of obesity, and I am delighted to see that AbbVie did not just in-license another incretin therapy (GLP-1 or GLP-1/GIP agonist ...

Petrelintide is part of an emerging class of drugs that bind to and activate the amylin receptor. The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion global collaboration and license agreement to develop petrelintide, an amylin ...